Short answer
LENZ Therapeutics, Inc. (LENZ) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2M with net income of −$41M.
Q1 2026 key financials · XBRL
- Revenue
- $2M
- Net income
- −$41M
- −183.8% YoY
- Operating margin
- -2321.7%
- EPS (diluted)
- −$1.32
- −149.1% YoY
Source: XBRL data from the LENZ Therapeutics, Inc. (LENZ) Q1 2026 10-Q on SEC EDGAR. USD.
LENZ Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.9M, versus $0 in Q1 2025, comprising $1.7M product sales and $250K license revenue
- VIZZ product sales, $1.7M, driven by approximately 25,000 paid and filled monthly prescriptions
- Net loss $41.5M vs $14.6M YoY; SG&A $45.0M vs $11.1M, up 305%
- Operating cash outflow $33.6M vs $16.0M YoY; cash, equivalents and securities $258.4M
- Management expects funding to positive operating cash flow, while citing rising commercialization expenses and possible additional financing needs
Risk Factors
- Newly added competition risk: FDA-approved Yuvezzi launched in March 2026, increasing presbyopia treatment alternatives
- Commercialization risk: VIZZ depends on access to approximately 15,000 ECPs prescribing over 85% of U.S. pharmaceutical presbyopia prescriptions
- Regulatory risk: VIZZ faces ongoing FDA cGMP compliance and post-marketing approval obligations
- Market risk: Generic Vuity launched in August 2025, potentially pressuring VIZZ adoption through lower pricing
- Financial risk: Net loss reached $41.5 million for the three months ended March 31, 2026, versus $14.6 million in 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LENZ Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.